Who We Are
Sirnaomics (2257.HK) is a leading global biopharmaceutical company dedicated to unlocking the full potential of RNA-targeted therapeutics.
Founded in 2007, we were built to solve the single greatest bottleneck in RNAi: effective drug delivery. Powered by our proprietary Peptide Nanoparticle (PNP) and GalAHead™ platforms, we deliver unrivaled precision in liver targeting while strategically expanding into high-value extrahepatic indications—including oncology, cardiometabolic disorders, and high-growth medical aesthetics.
We are pioneering a transformative shift in drug development: advancing beyond traditional protein-targeted therapies to direct RNA targeting, vastly expanding the universe of druggable targets and treatable diseases. This next-generation approach enables us to develop highly specific, durable, and purpose-built RNA therapeutics that go far beyond the limited potential of first-generation siRNA.
As a publicly listed enterprise (2257.HK) with multiple clinical-stage candidates advancing toward commercialization, Sirnaomics is more than a drug developer. We are defining the future of precision RNA medicine—delivering breakthrough innovation, scalable value, and transformative patient impact today.
Meet The Team
Dr. H. Fai Poon is Chief Executive Officer of Sirnaomics (2257.HK), overseeing corporate strategy, operations, and innovation. Under his leadership, the company continues to advance breakthrough RNAi therapeutics and strengthen its global industry leadership.
Bringing over 20 years of biotech and pharma experience, Dr. Poon founded QuaCell Biotechnology and led it from startup through a successful merger with Lepure Biotech, building scalable management systems. He previously held senior scientific roles at Hisun Bio and Merck, leading R&D programs for oncology and autoimmune disease drugs and supporting multiple IND and BLA approvals.
A respected academic contributor, he has published research in oncology and immunology and serves as a journal editor and peer reviewer. He earned his Ph.D. in Biochemistry from the University of Kentucky and an MBA in R&D Lean Management from the University of South Florida. A proven leader in innovation and growth, he drives Sirnaomics’ clinical and commercial progress.
Dr. Jake Tian is Group Senior Vice President of R&D and General Manager, China, at Sirnaomics (2257.HK). He leads strategic R&D planning, operational execution, and the development of a highly integrated, efficient R&D and manufacturing system, strengthening the company’s dual-delivery platform and accelerating pipeline progress.
Bringing more than 20 years of industry experience, Dr. Tian has deep expertise across small molecules, biologics, nucleic acid therapeutics, and complex generics, with full-cycle capabilities from early research to global regulatory submissions. He previously founded and led Shanghai and Suzhou Tansoon Pharmaceuticals as General Manager. Before that, he served as a key R&D leader at Hengrui Medicine, leading process development and registration for ADCs, insulin, and other complex therapeutics, with deep experience in nucleic acid delivery systems.
Dr. Tian holds a B.S. and M.S. in Chemistry from Nanjing University, a Ph.D. in Organic Chemistry from the University of Delaware, and completed postdoctoral research at The Scripps Research Institute.
Mr. Jerry Tse is Vice President of Operations at Sirnaomics (2257.HK). He drives IT and AI adoption across R&D, CMC, and clinical operations to improve efficiency and reduce costs, while overseeing supply chain, IT-AI, administration, and EHS systems to support scalable growth.
With nearly 20 years of operational leadership, Mr. Tse brings deep experience at publicly listed multinational corporations, including Compal Electronics (0320.HK) and Valuetronics Holdings Limited (BN2.SG), where he built scalable enterprise management systems. He later brought manufacturing-grade operational excellence to biotech at QuaCell Biotechnology, supporting its merger with Lepure Biotech.
He specializes in applying AI-powered lean operations and cost control from high-end manufacturing to biopharma. Mr. Tse holds a Master of Science degree from The Hong Kong Polytechnic University.
Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd.
Unit 415, A4 Building, No.218 Xinghu Street, Suzhou Industrial Park, Suzhou, PRC